Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID® (lenalidomide) in combination with rituximab (R2) demonstrated superior progression-free survival (PFS) in patients with relapsed/refractory indolent lymphoma compared to patients who received rituximab plus placebo (R-placebo). The data were presented by John Leonard, M.D. in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in S...